Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention?

Main Article Content

Silas Lendzele Sevidzem
Aubin Armel Koumba
Christophe Roland Zinga- Koumba
Nonvignon Marius Kedote
Gaël Darren Maganga
Essé Elvire Agossou
Safiatou Niaré- Doumbo
Bitsha-Kitime Dieudoné Kabkia
Luc Salako Djogbenou
Genevieve Lydie Acapovi- Yao
Idrissa Sarr
Julien Zahouli Bi Zahouli
Chimène Nze- Nkoghé
Rodrigue Mintsa- Nguema
Athanase Badolo
Emmanuel Kamba Mebourou
Jacques François Mavoungou
Fatou Bintou Sarr


The world is experiencing an outbreak due to the new and mysterious SARS-CoV-2. Information regarding its source and transmission dynamics in different environments as well as medications for its prevention and cure is weak. This review seeks to document on the epidemiology, clinical signs, control, prevention, and present some perspectives for SARS-CoV-2 research in Africa. There are geographical differences in morbidity and mortality rates of this disease all over the world. The scientific community strongly reject claims regarding the fact that the virus has been genetically manipulated, but supports the theory that it has a natural origin from animal host as any other emerging viral disease. Although animals are thought to be the original source of global spill over, person-to-person transmission is well comprehended. Transmission could be enhanced by symptomatic and asymptomatic individuals with high contaminations reported in dense urban environments. Scientific evidences from the Center for Disease Control (CDC) and other publications reported that contaminated surfaces and air could possibly be the underlying mechanism through which SARS-CoV-2 spreads. Cohort studies reveal that children as well as adults could be vulnerable to the disease, but others attribute it to health care workers, some risky habits (drinking and smoking) and comorbid individuals due to their immune suppressed status. There is no drug of choice for SARS-CoV-2, but clinical studies including several antiviral drugs are underway. Similarly, vaccine studies and clinical trial studies are ongoing. Because there is no medication, preventive measures such as Personal Protective Equipments (PPEs), ventilators, sanitation, social distancing, and quarantine are the gears globally used to curb the spread of this virus. The African continent does not have high morbidity and mortality compared to other continents that are highly affected. The following lessons could be learned by Africans from ongoing research: that the SARS-CoV-2 originated from an animal host, individuals could be infected irrespective of their age, sex, race, and origin, there is a broad spectrum of clinical signs and confirmatory diagnosis is required, there is no approved drug of choice, vaccine trials are ongoing and community-based prevention is required, the recommendations put in place by the Government and the WHO to curb the spread of this virus should be strictly followed. From the above lessons, a research project to study the ecological epidemiology of SARS-CoV-2 in tropical African settings by including the following aspects: socio-cultural, economic, and political characteristics as well as the evaluation of measures taken by the different countries to combat the disease is required.

SARS-CoV-2, epidemiology, clinical signs, chemotherapy, prevention, Africa

Article Details

How to Cite
Sevidzem, S. L., Koumba, A. A., Koumba, C. R. Z.-, Kedote, N. M., Maganga, G. D., Agossou, E. E., Doumbo, S. N.-, Kabkia, B.-K. D., Djogbenou, L. S., Yao, G. L. A.-, Sarr, I., Zahouli, J. Z. B., Nkoghé, C. N.-, Nguema, R. M.-, Badolo, A., Mebourou, E. K., Mavoungou, J. F., & Sarr, F. B. (2020). Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention?. Asian Journal of Medicine and Health, 18(6), 17-27.
Original Research Article


Huang C, WangY, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (Lond. Engl.). 2020;395:497–506.


CDC COVID-19 Response Team. Geographic Differences in COVID-19 Cases, Deaths, and Incidence-United States, February 12–April 7; 2020.

Miller A, Reandelar MJ, Fasciglione K, Violeta R, Li Y, Gonzalo HO. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: An epidemiological study. medRxiv and bioRxiv; 2020.


Calisher C, Dennis C, Rita C, Ronald BC, Daszak P, Drosten C, Enjuanes L, Farrar J, Hume F, Golding J. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. The Lancet; 2020.


Wu A, Yousong P, Baoying H, Xiao D, Xianyue W, Peihua N, Jing M, Zhaozhong Z, Zheng Z, Jiangyuan W, Jie S, Lijun Q, Zanxian X, Wenjie T, Genhong C, Taijiao J. Genome composition and divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host & Microbe. 2020a;7(1):325-328. DOI:

Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85–164.

De Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host factors in coronavirus replication. In Roles of Host Gene and Non-Coding RNA Expression in Virus Infection, Tripp, R.A., Tompkins, S.M., Eds.; Springer International Publishing: Cham, Switzerland. 2018;1–42.

Zhou P, Xing-Lou Y, Xian-Guang W, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Chao-Lin H, Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579,


Li X, Junjie Z, Qiang Z, Qing N, Yi L, Brian T, Chaillon A. Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. J Med Virol; 2020a.


Jin Y, Haiyan Y, Wangquan J, Weidong W, Shuaiyin C, Weiguo Z, Guangcai D. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12; 372.


Lam TTY, Shum MHH, Hua-Chen Z, Tong YG, Ni XB, Liao YS, Wei W, Cheung WYM, Li WJ, Li LF. Nature; 2020.


Li J, Yuan P, Heffernan J, Zheng T, Ogden N, Sander B, Jun L, Qi L, Jacques B, Kong JD. Observation wards and control of the transmission of COVID-19 in Wuhan. [Submitted]. Bull World Hlth Organ. E-pub; 2020b.


Ahmad T, Muhammad K. COVID-19: Zoonotic aspects. Travel Med Infect Dis; 2020. DOI:

Kristian GA, Rambaut A, Ian LW, Edward CH, Garry RF. The proximal origin of SARS-CoV-2. Nature Medecine; 2020.


Xu B, Bernardo G, Sumiko M, Kara S, Lauren G, Alyssa L, Emily LC, Yulin H, Hill SC, Maria MC. Epidemiological data from the COVID-19 outbreak, real-time case information. Scientific Data. 2020a;7:106.


Maganga GD, Pinto A, Mombo IM, Madjitobaye M, Beyeme AMM, Boundenga L, Gouilh MA, N’Dilimabaka N, Drexler JF, Drosten C, Leroy EM. Genetic diversity and ecology of coronaviruses hosted by cavedwelling bats in Gabon. Scientific Reports. 2020;10:7314.


Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmunity; 2020.


Mizumoto K, Chowell G. Transmission potential of the novel coronavirus (COVID-19) on board the Diamond Princess Cruises Ship, 2020. Infect Dis Model. 2020;5;264–270. DOI: .003

Zhao S, Cao P, Gao D, Zhuang Z, Chong MKC, Cai Y, Ran J, Wang K, Yang L, He D, Wang MH. Epidemic growth and reproduction number for the novel coronavirus disease (COVID-19) outbreak on the Diamond Princess Cruise Ship from January 20 to February 19, 2020: a preliminary data-driven analysis. SSRN; 2020.

DOI: .3543150

Doultree JC, Druce JD, Birch CJ, Bowden DS, Marshall JA. Inactivation of feline calicivirus, a Norwalk virus surrogate. J Hosp Infect. 1999;41:51–57.


Ong SWX, Tan YK, Chia PY, Lee TH, Wong MSY, Marimuthu K. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA; 2020.

DOI: .1001/jama.2020.3227

Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N. Engl J Med; 2020.

Fiorillo L, Gabriele C, Marco M, Cesare D, Giovanni S, Valeria P, Maria TF, Antonio M, Alessia LB, Giovanni LR. COVID-19 Surface Persistence: A recent data summary and its importance for medical and dental settings. Int J Environ Res Public Hlth. 2020;17:3132.


Borges do Nascimento IJ, Nensi C, Abdulazeem HM, Groote TCV, Umesh J, Ishanka W, Meisam AE. Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis. J Clin Med. 2020;9:941.

Hamid S, Mohammad YM, Rohela GK. Novel coronavirus disease (COVID-19): A pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbe and New Infect. 2020;35:100679.


Cecconi M, Daniele P, Enrico B, Alessio A, Massimiliano G, Michele C, Claudio A, Antonio V, Paolo O, Edoardo, V. For the Humanitas Covid-19 Task Force. J Clin Med. 2020;9:1548.


Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. International Urology and Nephrology; 2020.


Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. N Engl J Med; 2020.

DOI: 10.1016/S0140-6736(20)30211-7

Wu JT, Leung K, Leung GM. Now casting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study. Lancet. 2020b;395:689–697.


Fontanet A, Tondeur L, Madec Y, Grant R, Besombes C, Nathalie J, Pellerin SF, Ungeheuer MN, Cailleau I, Kuhmel L. Cluster of COVID-19 in northern France: A retrospective closed cohort study. MedRxiv and BioRxiv; 2020.


Tezer H, Bedir DT. Novel coronavirus disease (COVID-19) in children. Turkish J Med Sci. 2020;50:592-603.

Rodriguez-Morales AJ, Cardona-Ospina JA, Estefanía GO, Villamizar-Peña R, Yeimer HR, Juan PEA, Alvarado-Arnez. Clinical, Laboratory and Imaging Features of COVID-19: A systematic review and meta-analysis. Med Pharmacol; 2020.


Chaoqun Ma MD, Jiawei G, Pan H, Liang ZMD, Yuan B, Zhifu G, Hong W, Bili Z, Pan L, Xianxian Z. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: A systematic review and meta-analysis. MedRxiv; 2020.


Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) [published online ahead of print, 2020 Mar 27]. JAMA Cardiol. 2020;e201017.


Loeffelholz MJ, Tang YW. Laboratory Diagnosis of Emerging Human Coronavirus Infections-The State of the Art. Emerg Microbes Infect; 2020.

DOI: 10.1080/22221751.2020.1745095

Carlos WG, Dela C, Cao B, Pasnick S, Jamil S. Novel wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med. 2020;201(4):7–8.

DOI: 1164/rccm.2014P7

Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T. Identification of a Novel coronavirus causing severe pneumonia in human: A descriptive study. Chinese Med J; 2020.


Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020a;92(4):441– 447.


Longhitano L, Daniele T, Cesarina G, Giacomo L, Nicola T, Sara G, Giovanni LV, Giuseppe AP, Arcangelo L. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2. Int J Mol Sci. 2020;21:3622.


Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X. Coronavirus susceptibility to the antiviral remdesivir (gs-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221–18.


Tchesnokov EP, Feng JY, Porter DP, Gotte M. Mechanism of inhibition of ebola virus rna-dependent rna polymerase by remdesivir. Viruses. 2019;11(4):E326.


Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med. 2019;11(494):eaau9242.

DOI: scitranslmed.aau9242

PAAASLD-IDSA H. Guidance & Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10): 1477–92.

Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: A multicenter observational study. Clin Infect Dis; 2019.

DOI: [Epub ahead of print]

Cvetkovic RS, Goa KL. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs. 2013;63(8):769–802.

Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS. Role of lopinavir/ ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–6.

Attapon C, Ruangrong C. Promising Drug Candidates for 2019-Novel Coronavirus (COVID-19) Pneumonia. Acta Scientific Microbiol. 2020;3:4,01.

Dong L, Shasha H, Jianjun G. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discoveries & Therapeutics. 2020;14(1):58-60.

DOI: 10.5582/ddt.2020.01012

Hussin AR, Siddappa NB. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity; 2020.


Aguiar ACC, Murce E, Cortopassi WA, Pimentel AS, Almeida M, Barros DCS. Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist. 2018;8(3):459–64.

Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: An old drug against today's diseases? Lancet Infect Dis. 2003; 3(11):722–7.

Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19? International J Antimicrobial Agents; 2020.


Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015;38(3):E12.

Vincent MJ, Bergeron E, Benjanne S, Erickson BR, Rollin PE, Ksiazek TG. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2005;2:69.

Gautret P, Jean-Christophe L, Philippe P, Van TH, Line M, Morgane M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. International J Antimicrobial Agents; 2020.


Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res; 2020b.


Caly L, Julian DD, Mike GC, David A, Jans Kylie MW. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178.

Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc; 2020c.

DOI: 10.1097/JCMA.0000000000000270

Sanchez-Caballero S, Miguel AS, Miguel AP, Perez-Bernabeu E. An Efficient COVID-19 Prediction Model Validated with the Cases of China, Italy and Spain: Total or Partial Lockdowns? J Clin Med. 2020;9: 1547.


Chowdhury R, Heng K, Shawon MSR, Gabriel G, Okonofua D, Ochoa-Rosales C. On behalf of The Global Dynamic Interventions Strategies for COVID-19 Collaborative Group Dynamic interventions to control COVID-19 pandemic: A multivariate prediction modelling study comparing 16 worldwide countries. European J Epidemiol; 2020.


Kluge HHP, Kremlin W, Rippin HL, Mendes R, Peters DH, Kontsevaya A, Breda J. Prevention and control of non-communicable diseases in the COVID-19 response. The Lancet; 2020.


Cohen MS, Corey L. Combination prevention for COVID-19. Science. 2020; 368:551,

DOI: 10.1126/ 5798

Sevidzem SL, Mamoudou A, Kenne NB, Lontsi DM, Akoge I. HIV/AIDS infection prevalence in an agriculture-dominated rural community of west region of Cameroon. Asian Pacific Trop Med; 2016.


Sevidzem SL, Mamoudou A, Mfewou A. Typhoid, Malaria and their Concurrent infections in Fondonera, West Region of Cameroon. J Vet Sci Med Diagn. 2017;6:3.